People starting GLP-1 weight-loss therapy often have only a rough idea of what the next 12 months involve. The trial data describes group averages over fixed timeframes. The marketing material describes idealized outcomes. The actual shape of a first year (the adjustment, the dose changes, the slowdown, the plateau conversation, the maintenance question) is rarely laid out in plain terms.
This post is that framework. It walks through the phases of a first year: starting, early adjustment, dose changes, the slowing rate, the plateau conversation, and the maintenance question that emerges around month 12. It does not predict how much weight you will lose or when, and it gives no trial figures.
What the published trial is, and what it is not
The GLP-1 class includes semaglutide and tirzepatide; the GLP-1 medications on the TelePep store are listed on the programs page. The published evidence for tirzepatide comes from SURMOUNT-1 (Jastreboff et al., NEJM 2022), a 72-week randomized trial of branded tirzepatide in 2,539 adults with obesity, or with overweight plus a weight-related complication.1
Its results are averages across a trial population, measured with FDA-approved branded tirzepatide; compounded tirzepatide was not studied in those trials. They also come with the trial's structure (dose escalation on a fixed schedule and lifestyle counseling for everyone), which is not the same as any individual patient's care. Individual results are not predictable from a trial average. Our plain-English summary of SURMOUNT-1 covers the trial in more detail.
What follows is the shape of the year, not the size of the result.
Before month one: starting the protocol
Before the first injection:
- A licensed clinician reviews your intake and decides whether a prescription is appropriate
- Dose and schedule are set by the prescribing clinician and the pharmacy label
- Injection technique, storage, and dose tracking come from the pharmacy label and your prescriber's directions
- A conversation about the behavioral side (portion adjustment, hydration, protein intake)
The online visit does not include lab orders or lab review; your clinician may ask you to share recent results you already have.
This phase is often skipped or rushed by aggressive direct-pay platforms. It matters: the questions you ask now shape the follow-up conversations later in the year. See our framework on what legitimate prescribing looks like.
Month 1: initiation and accommodation
Dose: Set by your prescriber; this article gives none.
What is happening physiologically:
- Appetite signaling changes at the starting dose
- Gastric emptying begins to slow
- The body begins adapting to slower transit
What people commonly report:
- Nausea in the days after a weekly injection, most often early in treatment
- Reduced appetite, sometimes to the point of forgetting meals
- Possible constipation
- A sense that food "sits" longer
- The first taste of "this is different": eating less without forcing it
Common mistakes:
- Eating normal-sized portions and being surprised by nausea (smaller portions help)
- Underhydrating
- Trying to push diet hard at the same time (the medication is already reducing intake; let it work)
Side effects are something to report to your clinician, not something to manage by changing your dose on your own.
Month 2: dose review
Dose: Set by your prescriber; this article gives none.
What is happening:
- If the dose is increased, the weeks immediately after a change commonly bring renewed GI side effects, then settle
- Eating patterns are establishing: smaller portions start to feel normal
What people commonly report:
- A second wave of GI symptoms after a dose change, often milder than the first
- The realization that this is becoming the new normal
- Changes in how clothing fits
Clinical conversations:
- Confirm tolerability before any further dose change
- Discuss protein intake and resistance exercise to help preserve muscle while losing weight
Months 3-4: the steady phase
Dose: Set by your prescriber; this article gives none.
What is happening:
- The medication is producing its effect at the current dose
- Habits are forming (portion sizes, eating pace, food choices, hydration)
- Confidence in the routine increases
What people commonly report:
- Reduced food preoccupation: the "food noise" quieting, fewer intrusive thoughts about eating
- Clothes fitting differently
Things your clinician may discuss at this point:
- Adequate protein intake during weight loss
- Activity appropriate to your baseline fitness
- How often to check in so the clinician can review how things are going
Months 5-6: the rate may start to slow
Dose: Set by your prescriber; this article gives none.
What is happening:
- After meaningful weight loss, daily energy needs fall, so the same medication, dose, and habits can produce slower change than before
- This is a predictable physiologic adaptation, not a failure
What people commonly report:
- Some frustration that the pace feels slower
- Re-evaluation of whether the protocol is "still working"
- A temptation to cut calories further or push for a higher dose
Clinical conversations:
- Talk through the slowdown with your clinician rather than reacting to it alone
- Dose changes remain the clinician's call
Months 7-9: approaching plateau
Dose: Set by your prescriber; this article gives none.
What is happening:
- The body is approaching a new equilibrium weight
- Energy expenditure has adjusted downward
- Eating patterns are deeply established
What people commonly report:
- Increasing awareness that weight loss is leveling off
- Mixed feelings: pleased so far, uncertain about what comes next
- Questions about whether to continue, change medication, or accept the current weight
The plateau conversation:
- Is the plateau weight a clinically appropriate weight? Sometimes yes. Sometimes no.
- If your goal is still well below the plateau: discuss the options with your clinician.
- If the plateau weight is acceptable: shift focus to the clinician-managed maintenance plan.
Months 10-12: plateau and the maintenance question
Dose: Set by your prescriber; this article gives none.
What is happening:
- Weight is often at or near a new equilibrium
- "What comes next" is the central question
- You and your clinician discuss the maintenance plan
The three paths from here:
Path 1: Continue the current dose
For patients at a clinically appropriate weight, continuing the medication is the usual way to hold that weight.
Path 2: A lower maintenance dose
Your clinician may adjust the dose downward with the aim of preventing regain rather than driving further loss: useful for cost or side-effect reasons. Whether and how to do this is the clinician's decision.
Path 3: Try to discontinue
The published trial data on stopping (SURMOUNT-4, branded tirzepatide) points to regain after stopping.2 Compounded tirzepatide was not studied in that trial, and individual experience is not predictable from the average. Anyone considering discontinuation should plan it with their clinician, expect some regain, and have a clear reason for trying (cost, side effects, and so on).
For patients with a metabolic-disease context, continuing the medication at some dose is often the clinically appropriate path. Obesity is a chronic condition; GLP-1 medications are chronic-condition medications.
Beyond month 12
The 12-month mark is not a finish line. It is a transition point. Year two looks like:
- A stable dose and a stable routine
- Continued clinician follow-up and periodic reassessment
- Possibly a different medication if long-term tolerability points that way
The online visit does not include lab orders or lab review; your clinician may ask you to share recent results you already have.
It helps to treat year one as the steep-curve year and year two onward as the consolidation phase. The work does not end when the scale levels off.
Situations worth flagging
Some real-but-uncommon situations:
Less response than expected. Some people lose substantially less than the trial averages despite taking the medication as prescribed. If that is you a few months in, raise it with your prescriber; the options include continuing, adjusting, or changing medication.
More response than expected. Some people lose weight faster than expected. Rapid loss is a reason to check in, not a reason to push the dose.
Intolerable side effects. Some people cannot tolerate a dose their clinician considers therapeutic because of persistent GI side effects. A lower dose, a different medication, or a different approach are all things to discuss.
Plateau at a weight that does not meet clinical goals. Your clinician will discuss the options: dose adjustment, a different medication, behavioral or dietitian support, or referral to a higher level of care.
The honest framing
The SURMOUNT-1 result for branded tirzepatide is a population average from a trial of a branded product.1 Some participants did much better, some did much worse, and none of them were taking compounded tirzepatide. Your result is not predictable in advance.
What you can control, beyond the genetic and metabolic factors you cannot:
- Working with the dose your clinician sets. Not the highest dose: the one that produces progress you can tolerate.
- The behavioral side. Portion sizes, hydration, protein intake, resistance exercise. The medication does heavy lifting; the behaviors finish the job.
- Patience through the slowdown. The later months are slower than the early ones. Interpreting that as failure leads to poor decisions (pushing for dose increases, dropping out, switching unnecessarily).
- Honest conversations with your prescriber. Side effects, plateaus, switching considerations. The model works when patient and clinician communicate.
Bottom line
A first year on GLP-1 weight-loss therapy has a recognizable shape: adjustment, dose review, a steadier phase, a slowdown, the plateau conversation, and the maintenance question that defines year two. The only published numbers are population averages from trials of branded tirzepatide, and compounded tirzepatide was not studied in them; individual results are not predictable. Dose and schedule come from your prescribing clinician and the pharmacy label, never from a blog post. Plan the year, work the plan, and reassess at month 12 with a clinician who follows your case.
Editorial note: TelePeptide (the company) is a US direct-pay telehealth brand. The brand name is sometimes autocorrected to "telopeptide": an unrelated collagen biomarker; the two terms have no clinical connection.
Footnotes
-
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine 2022;387:205-216. DOI:10.1056/NEJMoa2206038. Branded tirzepatide; compounded tirzepatide was not studied. ↩ ↩2
-
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331(1):38-48. DOI:10.1001/jama.2023.24945. Branded tirzepatide; compounded tirzepatide was not studied. ↩
FAQ
Common questions
How much weight will I lose in the first year on GLP-1?
No one can tell you in advance. SURMOUNT-1, the 72-week trial of branded tirzepatide, reported averages across a trial population. Compounded tirzepatide was not studied in that trial, and individual results are not predictable from a trial average.
What happens in the first weeks?
The first weeks are an adjustment period: you follow the prescriber's directions and the pharmacy label, and report any side effects. What changes, and when, varies from person to person and is not predictable in advance. Raise any question with your prescribing clinician at follow-up.
When does the plateau hit?
There is no fixed month. In SURMOUNT-1 the published weight curves for branded tirzepatide flattened toward the end of the 72 weeks, but individual timing varies. A plateau is a new equilibrium, not a sign the medication has stopped working, and the right response is a conversation with your clinician rather than a change you make on your own.
Do I need to stay on GLP-1 forever?
Obesity is treated as a chronic condition, and the published trial evidence for branded tirzepatide (SURMOUNT-4) points to regain after stopping. Compounded tirzepatide was not studied in that trial. Whether and when to stop is a decision to make with your clinician.
What happens if I miss a few doses?
Follow the pharmacy label and your prescriber's directions on missed doses, and do not double up. If you have missed more than one dose in a row, contact your clinician before resuming; restarting after a gap sometimes means the clinician re-adjusts the dose.
Should I increase the dose every month?
No. Dose changes are the prescribing clinician's decision, made at follow-up based on how you are doing, and the schedule is set by the clinician and the pharmacy label. Never adjust your own dose. Steady progress at a dose you tolerate is the goal, not the highest dose.
Next Step
Talk to a licensed clinician
A licensed clinician will review your goals and tell you whether a medication on the TelePep store is appropriate. No insurance, no waiting room.
Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality.
TelePeptide offers direct-pay telehealth services. Independent licensed clinicians with Lone Star Virtual Health PLLC review every intake through the Bask Health platform and decide whether a prescription is appropriate. Prescriptions are filled by licensed US pharmacies; compounded medications are prepared by licensed US compounding pharmacies. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality.